Short Interest in Lisata Therapeutics, Inc. (NASDAQ:LSTA) Expands By 50.2%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 40,100 shares, a growth of 50.2% from the February 13th total of 26,700 shares. Currently, 0.6% of the company’s shares are sold short. Based on an average daily trading volume, of 41,400 shares, the days-to-cover ratio is presently 1.0 days.

Lisata Therapeutics Trading Down 0.4 %

Shares of LSTA stock traded down $0.01 during trading hours on Monday, reaching $2.38. The company’s stock had a trading volume of 3,291 shares, compared to its average volume of 21,722. The firm’s fifty day simple moving average is $2.78 and its 200 day simple moving average is $2.87. The stock has a market capitalization of $20.52 million, a P/E ratio of -0.95 and a beta of 1.16. Lisata Therapeutics has a one year low of $2.05 and a one year high of $4.20.

Lisata Therapeutics (NASDAQ:LSTA) last posted its earnings results on Thursday, February 27th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.21. The company had revenue of $1.00 million during the quarter. As a group, equities research analysts forecast that Lisata Therapeutics will post -2.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP lifted its stake in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 45.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,226 shares of the company’s stock after purchasing an additional 7,886 shares during the quarter. Dimensional Fund Advisors LP owned about 0.30% of Lisata Therapeutics worth $75,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Lisata Therapeutics in a research note on Wednesday, December 11th.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.